Company: DVAX
Filing Date: 2025-05-12
Form Type: DEFA14A
Source: 0000930413-25-001704
Chunk: 20

Company: DYNAVAX TECHNOLOGIES CORP
Filing Date: 2025-05-12
Form: DEFA14A
Chunk 20
---
 Filing) 5 - year TSR Through 17 - Apr - 2025 (DEFC14 Filing Date) 2 2

ibdroot \ projects \ IBD - NY \ dilates2022 \ 698484_1 \ Presentations \ 24. 2025.02.XX Fight Deck \ FINAL - to share with Cooley \ Dynavax Investor Presentation (May - 2025)_Print.pptx © Copyright DYNAVAX 2025 Deep Track’s Distortions Don’t Stop There (1/3) 29 | Deep Track claims our strategic pivot was “never - before - identified” Deep Track Investor Presentation – page 20 filed May 5, 2025 But the pivot Deep Track now claims is fabricated… … was clearly identified in SEC filings six years ago Source: https://www.sec.gov/Archives/edgar/data/1029142/00011931251 9155528/d753694d8k.htm Item 2.05 Costs Associated with Exit or Disposal Activities. On May 23, 2019, Dynavax Technologies Corporation (the ” Company “) announced a strategic organizational restructuring, to principally align its operations around its vaccine business and significantly curtail further investment in its immuno - oncology business . The Company also announced a reduction of its workforce by 82 positions, or approximately 37% of U.S. - based personnel. The Company expects the restructuring to be completed by year end. Total Stockholder Return Since Pivot 1 Source: FactSet; Market data as of 17 - Apr - 2025 1 Total stockholder return from 23 - May - 19, the date that DVAX announced its strategic pivot, to 17 - Apr - 2025, the date of Dynavax’s definitive proxy filing. 2 Vaccine Peers comprised of Bavarian Nordic, Emergent BioSolutions, Novavax, Valneva, and Vaxcyte; Vaxcyte TSR from IPO on 12 - Jun - 2020 to pricing date, 17 - A pr - 2025. 2 62 % (7)% (2)% Dynavax S&P 500 Biotechnology Select Industry Index (XBI) Vaccine Peers

ibdroot \ projects \ IBD - NY \ dilates2022 \ 698484_1 \ Presentations \ 24. 2025.02.XX Fight Deck \ FINAL - to share with Cooley \ Dynavax Investor